Qurin, founded in 2017 and headquartered in The Netherlands, is strategically positioned at the intersection of biotechnology and health care. The company is set on revolutionizing cancer diagnostics with its slogan, "Early cancer detection." Utilizing advanced technologies, Qurin integrates artificial intelligence, human genomics, and nanotechnology to create diagnostic solutions aimed at early cancer detection, addressing a critical healthcare gap.
Given that cancer remains a leading cause of death globally, primarily due to the lack of early screening, Qurin's mission carries both significant human and socio-economic impact. The potential to positively influence patient quality of life and reduce societal burdens is substantial.
The company's progress has garnered investor interest, with a notable spinout investment from Twente on 01 January 2017. This backing underscores confidence in Qurin's innovative approach and market potential.